In the ARON trial, in situations of diagnostic uncertainty and when the CRP result fails to rule out the possibility of a serious infection (i.e. CRP is not under 5 mg/L), clinicians are directed to consult the Belgian Commission for the Coordination of Antibiotic Policy (BAPCOC) guidelines for antibiotic prescription decisions. The gene discussed is CRP; the disease is infection.